Carlo Zanon

Carlo Zanon

Auto-generated profile, based on publicly available information

Carlo Zanon

Bioinformatics Core Facility, Istituto di Ricerca Pediatrica Fondazione Città Della Speranza, 35127, Padova, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2011 in Leukemia & Lymphoma
Verified
Journal Article
Open access
PDF file
LRLudovica Riera
Ludovica Riera
ELElena Lasorsa
Elena Lasorsa
LBLisa Bonello
Lisa Bonello
FSFrancesca Sismondi
Francesca Sismondi
FTFabrizio Tondat
Fabrizio Tondat
GIGiorgio Inghirami
Giorgio Inghirami
Gain-of-function (GOF) mutations of Janus kinase 2 (JAK2) are frequently seen in myeloproliferative disorders (MPDs). Meanwhile, JAK3 activating substitutions have been found in a few megakaryocytic cell lines and in primary myeloid leukemia (AMKL). Here, we sought to discover novel leukemogenetic mutations in de novo acute myeloid leukemia of non-Down syndrome (N-DS) by DNA sequencing. A total of 191 normal Caucasian individuals were studied to define single nucleotide polymorphisms (SNPs) within the JH2 and JH6 domains. Although known activating substitutions were observed in rare cases of acute myeloid leukemia (AML) (V722I [2/134] or P132T [1/119]), all samples were wild-type (WT) for the oncogenic A572V (119/119). Interestingly, a novel homozygous mutation (P132A) was discovered in a patient with acute megakaryoblastic leukemia and in vivo studies demonstrated that its ectopic expression was oncogenic in a mouse xenotransplant model. This study defines a novel JAK3 mutation among patients with N-DS AML and demonstrates that normal individuals can also display germline JAK3 substitutions, previously proven to have oncogenic properties, in vitro and in vivo. The discovery of these substitutions in normal donors encourages future studies to define new risk factors among patients with MPDs.

27 February 2023 in Materials Today Bio
Verified
Journal Article
Open access
RNRamin Nasehi
Ramin Nasehi
AAAli T. Abdallah
Ali T. Abdallah
MPMarcella Pantile
Marcella Pantile
CZCarlo Zanon
Carlo Zanon
MVMichael Vogt
Michael Vogt
SASanja Aveic
Sanja Aveic
A key challenge for the discovery of novel molecular targets and therapeutics against pediatric bone metastatic disease is the lack of bona fide in vitro cell models. Here, we show that a beta-tricalcium phosphate (β-TCP) multicellular 3D in vitro bone microtissue model reconstitutes key phenotypic and transcriptional patterns of native metastatic tumor cells while promoting their stemness and proinvasive features. Comparing planar with interconnected channeled scaffolds, we identified geometry as a dominant orchestrator of proangiogenic traits in neuroblastoma tumor cells. On the other hand, the β-TCP-determined gene signature was DNA replication related. Jointly, the geometry and chemical impact of β-TCP revealed a prometastatic landscape of the engineered tumor microenvironment. The proposed 3D multicellular in vitro model of pediatric bone metastatic disease may advance further analysis of the molecular, genetic and metabolic bases of the disease and allow more efficient preclinical target validations.

1 November 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
SHS. Hobor
S. Hobor
SMS. Misale
S. Misale
ECE. Crowley
E. Crowley
ESElisa Scala
Elisa Scala
CZC. Zanon
C. Zanon
ABA. Bardelli
A. Bardelli

24 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RAR. Angioni
R. Angioni
MBM. Bonfanti
M. Bonfanti
NCN. Caporale
N. Caporale
RSR. Sánchez-Rodríguez
R. Sánchez-Rodríguez
FMF. Munari
F. Munari
GTG. Testa
G. Testa
The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.

3 April 2023
Verified
Other
Open access
ABAlberto Bardelli
Alberto Bardelli
Simona CorsoSimona Corso
Simona Corso
ABAndrea Bertotti
Andrea Bertotti
SHSebastijan Hobor
Sebastijan Hobor
EVEmanuele Valtorta
Emanuele Valtorta
SSSalvatore Siena
Salvatore Siena
Supplementary Figure S4 - PDF file 19K, Ectopic expression of MET in cetuximab sensitive DIFI and LIM1215 cell lines

3 April 2023
Verified
Other
Open access
ABAlberto Bardelli
Alberto Bardelli
Simona CorsoSimona Corso
Simona Corso
ABAndrea Bertotti
Andrea Bertotti
SHSebastijan Hobor
Sebastijan Hobor
EVEmanuele Valtorta
Emanuele Valtorta
SSSalvatore Siena
Salvatore Siena